Leap Therapeutics (LPTX) shares were down nearly 13% in recent trading Wednesday after Baird and HC Wainwright downgraded the stock to neutral.
Baird also trimmed its price target to $1.25 from $9. The stock was previously rated outperform at Baird and buy at HC Wainwright.
Almost 3 million shares traded so far, compared with a daily average of about 612,000.
Price: 0.57, Change: -0.08, Percent Change: -12.92
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。